Neurology:小儿心脏骤停后神经结果评估工具研究

2018-06-12 zhangfan MedSci原创

研究认为PRCA评分是小儿心脏骤停患者神经学结果描述强有力的方法,为神经功能损伤、领域特异性损伤以及神经行为结果指标之间的相关性研究提供工具

近日研究人员就在儿童心脏骤停研究中(THAPCA)治疗性低温疗法对幸存者12个月后神经功能的影响评估方法进行了研究。

出生后48小时-18岁的非成年患者参与研究,在心脏骤停后处于昏迷,随机接受治疗性低温或常温治疗,主要终点是幸存者12个月后神经行为结果(VABs-Ⅱ评分)。总计181名幸存者参与评估,使用半定量小儿心脏骤停复苏(PRCA)评估量表对6个领域进行了评分,评分范围从0(无缺陷)到21(最大缺陷)。比较PRCA评分、12个月VABs-Ⅱ评分和认知评分的差异及相关性。

PRCA评分结果如下:81人(45%)得分0-3分,为无/极小损伤;24人(13%)得分4-7分,为轻微损伤;11人得分8-11分,为中度损伤;15人(8%)得分12-16为重度损伤;39人(21%)得分17-21分为极重度损伤。VABS-II得分与PRCA分类以及认知得分的相关性极为显著。不良预后相关因素包括出院后心脏骤停、早期发作和出院时的神经状况差。

研究认为PRCA评分是小儿心脏骤停患者神经学结果描述强有力的方法,为神经功能损伤、领域特异性损伤以及神经行为结果指标之间的相关性研究提供工具。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950422, encodeId=08c519504223b, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Feb 27 20:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000454, encodeId=f4cc20004543c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 20 09:29:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046745, encodeId=74d32046e4555, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Thu Apr 11 14:29:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323522, encodeId=15ab32352239, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 12 09:59:03 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950422, encodeId=08c519504223b, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Feb 27 20:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000454, encodeId=f4cc20004543c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 20 09:29:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046745, encodeId=74d32046e4555, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Thu Apr 11 14:29:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323522, encodeId=15ab32352239, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 12 09:59:03 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
    2018-10-20 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950422, encodeId=08c519504223b, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Feb 27 20:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000454, encodeId=f4cc20004543c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 20 09:29:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046745, encodeId=74d32046e4555, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Thu Apr 11 14:29:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323522, encodeId=15ab32352239, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 12 09:59:03 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950422, encodeId=08c519504223b, content=<a href='/topic/show?id=dfd4e8626e1' target=_blank style='color:#2F92EE;'>#结果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78626, encryptionId=dfd4e8626e1, topicName=结果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Wed Feb 27 20:29:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000454, encodeId=f4cc20004543c, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Sat Oct 20 09:29:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046745, encodeId=74d32046e4555, content=<a href='/topic/show?id=fd539148067' target=_blank style='color:#2F92EE;'>#评估工具#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91480, encryptionId=fd539148067, topicName=评估工具)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8fc0211, createdName=doctor-chen9582, createdTime=Thu Apr 11 14:29:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323522, encodeId=15ab32352239, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Tue Jun 12 09:59:03 CST 2018, time=2018-06-12, status=1, ipAttribution=)]
    2018-06-12 龙胆草

    学习谢谢分享

    0

相关资讯

Diabetes Care:哪种磺脲类药物对心脏骤停及室性心律失常更安全?

2018年4月,发表于《Diabetes Care》上的一项研究,对磺脲类药物的安全性进行了对比,考察了其心脏骤停及室性心律失常(SCA/VA)的风险。

Circulation:年轻人发生心源性猝死的风险因素,运动为少数人的触发诱因!

预防年轻人心脏骤停(SCA)仍是一尚未解决的公共健康问题,而体育活动已明确是一诱因。尽管现有的年轻人标准心血管风险因素与其成年后的发病率和死亡率相关,但这些风险因素对年轻人发生心脏骤停的关联尚未证实。现有研究人员于2002-2015年对美国波特兰、俄勒冈州和大都会区5-34岁的发生过SCA的人群进行研究。通过对紧急反应记录、终生临床记录和尸检进行详细分析,以此评估患者的情况、复苏预后和临床资料。此

NEJM病例:是谁,夺去了这位年轻女性的心跳?

“铃铃铃”,急诊室的电话突然响起,电话另一头传来一位女性急促的声音:“医生,快来救救我的女儿,她现在倒在地上,已经没有心跳了”。

Circulation:尽早应用肾上腺素可明显提高院外心脏骤停患者的存活率

既往研究证明尽早应用肾上腺素可提高休克性初始心律性院外心脏骤停(OHCA)患者的存活率。但肾上腺素应用时间对非休克性初始心律患者的效应尚不明确。现有研究人员对肾上腺素应用时间和急救医疗服务(EMS)治疗的非休克性初始心律的OHCA成人和儿童患者的存活率的关联进行探究。研究人员对2011年6月4日-2015年6月30日复苏预后联网前瞻性鉴定的OHCAs进行二次分析。纳入EMS治疗的非休克性心律的OH

Circulation:快速除颤(≤2min)和肾上腺素治疗(≤5min)可大大提高心脏骤停患者的长期存活率!

既往研究报道在医院内心脏骤停(IHCA)的患者,及时予以除颤和肾上腺素治疗可大大提高住院存活率。但这种存活率优势在出院后是否还持续存在尚不明确。研究人员通过检索国家IHCA医疗记录(2000年-2011年间、517家医院)共筛出36961位(年龄≥65岁)IHCA患者。由无脉搏性室性心动过速或室颤导致的IHCA患者,分为快速除颤(≤2min)和延迟除颤(>2min);由心脏骤停或无脉搏性电活动引起

Crit Care Med:心脏骤停患者使用哪种血管活性药物能获得更好结局?

2018年5月,发表在《Crit Care Med》的一项由意大利、英国和瑞士科学家进行的网状Meta分析,考察了心肺复苏期间使用的血管活性药物方案对生存率和神经病学结局的影响。